Vertero Therapeutics, Inc. Email Format
Biotechnology ResearchMassachusetts, United States11-50 Employees
Vertero Therapeutics, Inc. is a biotechnology research company focused on developing therapies that address neurodegenerative diseases by targeting the peripheral nervous system. Its lead program, VT-5006, aims to modulate a gut-related target implicated in protein aggregation and inflammation associated with Parkinson’s disease, with a planned Phase 1 clinical trial. The firm is pursuing additional asset development, including a candidate addressing bile acid dysregulation for undisclosed indications. Based in Woburn, Massachusetts, Vertero operates as a clinical-stage organization with a pipeline designed to intervene downstream in neurodegenerative disease pathways. The company is positioned within the biotechnology research sector, emphasizing therapeutic approaches that act outside the brain to influence disease progression. Recent leadership changes and a Series D financing in 2025 reflect ongoing organizational development and clinical advancement efforts.